- Home
- HHS vs CLNN Comparison
HHS vs CLNN Comparison
Compare HHS & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- CLNN
- Stock Information
- Founded
- HHS 1923
- CLNN 2012
- Country
- HHS United States
- CLNN United States
- Employees
- HHS N/A
- CLNN N/A
- Industry
- HHS Advertising
- CLNN Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- CLNN Health Care
- Exchange
- HHS Nasdaq
- CLNN Nasdaq
- Market Cap
- HHS 37.4M
- CLNN 43.0M
- IPO Year
- HHS N/A
- CLNN N/A
- Fundamental
- Price
- HHS $5.19
- CLNN $4.79
- Analyst Decision
- HHS
- CLNN Strong Buy
- Analyst Count
- HHS 0
- CLNN 4
- Target Price
- HHS N/A
- CLNN $55.25
- AVG Volume (30 Days)
- HHS 24.8K
- CLNN 69.0K
- Earning Date
- HHS 03-13-2025
- CLNN 03-12-2025
- Dividend Yield
- HHS N/A
- CLNN N/A
- EPS Growth
- HHS N/A
- CLNN N/A
- EPS
- HHS N/A
- CLNN N/A
- Revenue
- HHS $187,604,000.00
- CLNN $421,000.00
- Revenue This Year
- HHS N/A
- CLNN N/A
- Revenue Next Year
- HHS $4.05
- CLNN N/A
- P/E Ratio
- HHS N/A
- CLNN N/A
- Revenue Growth
- HHS N/A
- CLNN N/A
- 52 Week Low
- HHS $4.85
- CLNN $3.82
- 52 Week High
- HHS $8.87
- CLNN $11.00
- Technical
- Relative Strength Index (RSI)
- HHS 42.75
- CLNN 46.32
- Support Level
- HHS $5.04
- CLNN $4.75
- Resistance Level
- HHS $5.20
- CLNN $5.06
- Average True Range (ATR)
- HHS 0.26
- CLNN 0.38
- MACD
- HHS 0.02
- CLNN -0.06
- Stochastic Oscillator
- HHS 45.95
- CLNN 2.60
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).